KEY FEATURES
| Full Name | Fc Fragment Of IgG Low Affinity IIIb Receptor |
|---|---|
| Synonym | CD16b; CD16-B; FCGR3-B; FCG3; FcgRIII; Low affinity immunoglobulin gamma Fc region receptor III-B |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 0.31-20ng/mL |
| Sensitivity | 0.14ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human FcgR3B in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human FcgR3B. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human FcgR3B and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human FcgR3B, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human FcgR3B. You can calculate the concentration of Human FcgR3B in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human FcgR3B ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 0.97 | 3.13 | 8.22 | 1.05 | 3.23 | 7.48 |
| Standard deviation | 0.06 | 0.16 | 0.32 | 0.07 | 0.14 | 0.39 |
| CV(%) | 6.07 | 5.15 | 3.9 | 6.72 | 4.2 | 5.16 |
RECOVERY
The recovery of Human FcgR3B spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 85-98 | 90 |
| EDTA plasma (n=8) | 92-105 | 98 |
| Cell culture media (n=8) | 86-96 | 91 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human FcgR3B in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with FCGR3B ELISA Kits
| SYK ELISA Kit | publications with FCGR3B and SYK |
Pathways associated with FCGR3B ELISA Kit
| Leishmaniasis Pathway | Leishmaniasis Pathway |
| Natural Killer Cell Mediated Cytotoxicity Pathway | Natural Killer Cell Mediated Cytotoxicity Pathway |
| Osteoclast Differentiation Pathway | Osteoclast Differentiation Pathway |
| Phagosome Pathway | Phagosome Pathway |
| Staphylococcus Aureus Infection Pathway | Staphylococcus Aureus Infection Pathway |
Diseases associated with FCGR3B ELISA Kit
| Inflammation | publications with FCGR3B and Inflammation |
| Cardiovascular Diseases | publications with FCGR3B and Cardiovascular Diseases |
| Necrosis | publications with FCGR3B and Necrosis |
| Syndrome | publications with FCGR3B and Syndrome |
| Sepsis | publications with FCGR3B and Sepsis |
| Agranulocytosis | publications with FCGR3B and Agranulocytosis |
| Pain | publications with FCGR3B and Pain |
| Wegener Granulomatosis | publications with FCGR3B and Wegener Granulomatosis |
| Pleural Effusion | publications with FCGR3B and Pleural Effusion |
| Proteinuria | publications with FCGR3B and Proteinuria |
Organs/Tissues associated with FCGR3B ELISA Kit
| Blood | publications with FCGR3B and Blood |
| Kidney | publications with FCGR3B and Kidney |
| Lung | publications with FCGR3B and Lung |
| Uterus | publications with FCGR3B and Uterus |
| Liver | publications with FCGR3B and Liver |
| Placenta | publications with FCGR3B and Placenta |
| Brain | publications with FCGR3B and Brain |
| Prostate | publications with FCGR3B and Prostate |
| Pancreas | publications with FCGR3B and Pancreas |
| Stomach | publications with FCGR3B and Stomach |